Neural patterns predicted which participants classified as high or low performers based on attention networks during the game. LOS ANGELES--(BUSINESS WIRE)--Kernel, a leader in non-invasive ...
TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today announced that ...
LOS ANGELES--(BUSINESS WIRE)-- Kernel, a leader in non-invasive neuroimaging, announces the publication of their study "Measuring acute effects of subanesthetic ketamine on cerebrovascular ...
Please provide your email address to receive an email when new articles are posted on . Neurotechnology firm Kernel and biopharmaceutical company Cybin announced promising pilot results from a ...
- Results to be presented at PSYCH Symposium taking place in London on May 11, 2022 - LOS ANGELES & TORONTO--(BUSINESS WIRE)--Kernel, a leader in non-invasive neuroimaging, and Cybin Inc. (NEO:CYBN) ...
At last year's SPIE Photonics West, California-based neurotech start-up Kernel revealed the system architecture of its proposed Kernel Flux optically-pumped magnetometer platform designed to record ...
New feasibility study indicates that VR has the potential to drive physiological changes in the body and brain associated with pain relief LOS ANGELES, Feb. 8, 2024 /PRNewswire/ -- AppliedVR ®, a ...
The first study visit to measure the psychedelic effects of ketamine in the cerebral cortex blood flow is underway, announced Cybin Inc. CYBN, which is sponsoring the research that will make heavy use ...
“The commencement of the Kernel feasibility study marks a truly exciting moment, not only for Cybin and Kernel, but also for the entire field of psychedelic drug development. To this point, studies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results